Abstract:Abstract Aims To investigate the prevalence of familial hypercholesterolaemia (FH) and compare the performance of clinical criteria and genetic testing in patients undergoing coronary angiography. Methods and results The prevalence of FH was determined with the Dutch Lipid Clinical Network (DLCN), US ‘Make Early Diagnosis to Prevent Early Death’ (US-MEDPED), Simon Broome (SB) criteria, the ‘familial hypercholesterolaemia case ascertainment tool’ (FAMCAT), and a clinical algorithm. Genetic screening was conducted with a custom array from Affymetrix (CARRENAL array) harbouring 944 FH mutations. The study cohort consisted of 3267 patients [78.6% with coronary artery disease (CAD)]. FH was diagnosed in 2.8%, 2.2%, 3.9%, and 7.9% using the DLCN, US-MEDPED, SB criteria, and the FAMCAT. The clinical algorithm identified the same patients as the SB criteria. Pathogenic FH mutations were found in 1.2% (1.2% in patients with CAD, 1.0% in patients without CAD). FH was more frequently diagnosed in younger patients. With genetic testing as reference, the clinical criteria achieved areas under the ROC curve [area under the curves (AUCs)] in the range of 0.56–0.68. Using only low-density lipoprotein cholesterol (LDL-C) corrected for statin intake, an AUC of 0.68 was achieved. Conclusion FH is up to four-fold more prevalent in patients undergoing coronary angiography than in contemporary cohorts representing the general population. Different clinical criteria yield substantially different diagnosis rates, overestimating the prevalence of FH compared with genetic testing. LDL-C testing alone may be sufficient to raise the suspicion of FH, which then needs to be corroborated by genetic testing. Lay summary In this study, we investigated the frequency of familial hypercholesterolaemia—a common genetic condition leading to markedly elevated low-density lipoprotein (LDL) cholesterol and increased risk of atherosclerosis—in 3267 patients undergoing coronary angiography according to commonly used diagnostic scoring systems and genetic testing. Genetically confirmed familial hypercholesterolaemia was four-fold more prevalent in patients undergoing coronary angiography compared with contemporary cohorts representing the general population, and was more often diagnosed in younger patients.Compared with genetic testing—the gold standard to diagnose familial hypercholesterolaemia—the diagnostic scoring systems only modestly discriminated between healthy individuals and those with familial hypercholesterolaemia. Importantly, LDL cholesterol testing alone provided equivalent diagnostic information compared with any of the scores.

Peripheral artery disease: an underdiagnosed condition in familial hypercholesterolemia? A systematic review

Consensus document on diagnosis and management of Familial Hypercholesterolemia from the Italian Society for the study of Atherosclerosis (SISA)

Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy

Familial Hypercholesterolemia: Current Limitations and Future Breakthroughs

Advances in familial hypercholesterolemia

Epidemiology of atherosclerotic cardiovascular disease in polygenic hypercholesterolemia with or without high lipoprotein(a) levels

Influence of Polygenic Background on the Clinical Presentation of Familial Hypercholesterolemia

Prevalence and prognosis of molecularly defined familial hypercholesterolemia in patients with acute coronary syndrome

Familial Hypercholesterolemia in the Elderly: An Analysis of Clinical Profile and Atherosclerotic Cardiovascular Disease Burden from the Hellas-FH Registry

Clinical and angiographic characteristics of patients with familial hypercholesterolemia presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Familial Hypercholesterolemia Accompanying Atherosclerosis:A Case Report and Review of Literature

Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)

Prevalence and management of familial hypercholesterolaemia in patients with chest pain admitted to hospital: a retrospective observational study

Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors

Clinical and genetic diagnosis of familial hypercholesterolaemia in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

FAMILIAL HYPERCHOLESTEROLAEMIA - A DIAGNOSIS THAT EVERY PLASTIC SURGEON CAN EXPERIENCE

Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE

Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia

Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism

Physical signs and atherosclerotic cardiovascular disease in familial hypercholesterolemia: the HELLAS-FH Registry